These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 16705118

  • 1. Celecoxib shown effective in preventing colon polyps.
    Nelson NJ.
    J Natl Cancer Inst; 2006 May 17; 98(10):665-7. PubMed ID: 16705118
    [No Abstract] [Full Text] [Related]

  • 2. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Meyer CH.
    Klin Monbl Augenheilkd; 2005 Jan 17; 222(1):62-3. PubMed ID: 15678404
    [No Abstract] [Full Text] [Related]

  • 3. Clinical trials. Halt of Celebrex study threatens drug's future, other trials.
    Couzin J.
    Science; 2004 Dec 24; 306(5705):2170. PubMed ID: 15618492
    [No Abstract] [Full Text] [Related]

  • 4. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Jugdutt BI.
    Circulation; 2007 Jan 23; 115(3):288-91. PubMed ID: 17242292
    [No Abstract] [Full Text] [Related]

  • 5. The pain game.
    Wadman M.
    Nature; 2007 Jul 26; 448(7152):400-1. PubMed ID: 17653159
    [No Abstract] [Full Text] [Related]

  • 6. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Couzin J.
    Science; 2005 Feb 25; 307(5713):1183-5. PubMed ID: 15731414
    [No Abstract] [Full Text] [Related]

  • 7. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR.
    Yao Xue Xue Bao; 2005 Nov 25; 40(11):967-9. PubMed ID: 16499077
    [No Abstract] [Full Text] [Related]

  • 8. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH, Sichrovsky T.
    Am J Cardiol; 2005 Sep 15; 96(6):872-3. PubMed ID: 16169380
    [No Abstract] [Full Text] [Related]

  • 9. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.
    Pharmacoepidemiol Drug Saf; 2003 Sep 15; 12(1):67-70. PubMed ID: 12616850
    [No Abstract] [Full Text] [Related]

  • 10. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM.
    N Engl J Med; 2005 Mar 17; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract] [Full Text] [Related]

  • 11. Clinical trials. Nail-biting time for trials of COX-2 drugs.
    Couzin J.
    Science; 2004 Dec 03; 306(5702):1673-5. PubMed ID: 15576585
    [No Abstract] [Full Text] [Related]

  • 12. Institutional review boards must conduct safety review.
    Maloney DM.
    Hum Res Rep; 2005 Feb 03; 20(2):3. PubMed ID: 15839005
    [No Abstract] [Full Text] [Related]

  • 13. Raising the safety bar--the FDA's coxib meeting.
    Okie S.
    N Engl J Med; 2005 Mar 31; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar 13; 145(11):60. PubMed ID: 12688204
    [No Abstract] [Full Text] [Related]

  • 16. COX-2 inhibitors and cardiovascular toxicity: a class effect?
    Laible B.
    S D J Med; 2005 Mar 13; 58(3):93-4. PubMed ID: 15794479
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
    Vanchieri C.
    J Natl Cancer Inst; 2005 Apr 20; 97(8):552-3. PubMed ID: 15840872
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.